CooperSurgical, Inc. Launches PGTai Technology Platform and ERPeak Endometrial Receptivity Test
TRUMBULL, Conn., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CooperSurgical, Inc. announced the launch of the CooperGenomicsSM PGTaiSM technology platform and ERPeakSM endometrial receptivity test at ASRM 2018.
The PGTaiSM technology platform is a ground-breaking platform that harnesses the power of artificial intelligence (AI) and machine learning to improve PGT-A calling, interpretation, and reporting. Built on data of 1000+ biopsies that led to healthy babies, a vastly larger dataset for baseline than other available PGT-A software in use today, the PGTaiSM technology platform provides robust data analysis, reporting and interpretation. To ensure the platform was ready for any clinical situation, sequencing data from 10,000+ embryos and 5 million data points were analysed by the PGTaiSM technology platform and reviewed for accuracy in interpretation and reporting. This breakthrough improves accuracy of interpretation and reporting while removing subjectivity and avoiding transcription errors.
“As someone who has read tens of thousands of PGT-A results, I’m really excited about the impact that the PGTaiSM technology platform will have on our labs. The PGTaiSM technology platform project began as an initiative to simply improve our analytical process. As we reviewed our methods, it just didn’t make sense to me that we take a sophisticated approach like sequencing and reduce all of that data down to a simple image. With that in mind, and given recent advances in data science, it was clear to us that deploying machine learning and AI was the way to go,” said Mike Large PhD, Senior Director R&D for CooperSurgical Fertility and Genomic Solutions.
Processed on CooperSurgical’s custom-developed and validated platform, the new ERPeakSM endometrial receptivity test offers accurate and reliable detection of the receptivity status of a woman’s endometrium, helping inform optimal embryo transfer timing. “The progress we’ve made in the last 15 years of embryo genetics, culminating with PGTaiSM platform, have been truly impressive. That said, when we look at the SART data, we’re hard pressed to achieve pregnancy rates north of 60%. As we investigated opportunities to improve fertility outcomes, the endometrium was an obvious choice,” said Josh Blazek PhD, Senior Director R&D for CooperSurgical Fertility and Genomic Solutions, a CooperSurgical, Inc. business segment.
The ERPeakSM test adds to CooperSurgical Fertility and Genomic Solutions’ market leading preimplantation genetic testing (PGT) portfolio and reinforces CooperSurgical Fertility and Genomic Solutions’ position as the comprehensive provider of IVF laboratory and genetic testing solutions.
“As the leading company in PGT, we are excited to offer these new and innovative products to our customers. CooperSurgical Fertility and Genomic Solutions is committed to investing and innovating in the reproductive genetic testing space and these products represent the first of many exciting products that we have in the pipeline” said Tony Gordon PhD, VP Business Development for CooperSurgical Fertility and Genomic Solutions.
The PGTaiSM technology platform and ERPeakSM endometrial receptivity test will be available to order in North America from November 1, 2018. Both will be available internationally starting January 2019.
About CooperSurgical Fertility and Genomic SolutionsCooperSurgical Fertility and Genomic Solutions, a unit of CooperSurgical, Inc., is the global leader of IVF and reproductive genetics, providing innovative and best-in-class products and services for every step in the ART journey. Building on the high-quality reputation of our legacy companies ORIGIO, Research Instruments, The Pipette Company, K-Systems, Wallace, LifeGlobal and CooperGenomics, we provide a trusted system of consumables, equipment, technologies and genetic testing for the complete ART process. CooperGenomics’ expert scientists pioneered preimplantation genetic testing and continue to innovate and advance the field through cutting-edge research. For more information, please visit coopersurgical.com.
About CooperSurgical CooperSurgical, a unit of The Cooper Companies, Inc. (NYSE:COO), services the health care market advancing the health of families through a diversified portfolio of products and services focusing on women’s health, including fertility, diagnostics, and contraception. CooperSurgical has established its market presence and distribution system by developing products and acquiring companies, products and services that complement its business model. We categorize CooperSurgical product sales based on the point of health care delivery which includes products used in medical offices and surgical procedures primarily by obstetricians and gynecologists as well as fertility products/equipment and genetic testing services used in fertility clinics and laboratories. CooperSurgical has major manufacturing and distribution facilities in Connecticut, Texas, Denmark, Costa Rica and various smaller international locations, with diagnostic facilities located in multiple locations including California, New Jersey, Texas, and internationally in Canada and the United Kingdom.
About The Cooper Companies The Cooper Companies, Inc. (“Cooper”) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of families with its diversified portfolio of products and services focusing on women’s health, fertility and diagnostics. Headquartered in Pleasanton, Calif., Cooper has more than 12,000 employees with products sold in over 100 countries. For more information, please visit coopercos.com.
Contact:Rishi JoshiGlobal Product Director(+44) 7535-610375 Rishi.Joshi@coopergenomics.com